Background: The selection of therapies for breast cancer is today based on prognostic features (chemotherapy, radiotherapy), hormone receptor status (hormonal therapy) and HER-2 status (trastuzumab therapy). HER-2, p53 and BCL-2 are tumour-related proteins that have the potential to further improve individualisation of patient management, by predicting response to chemotherapy, hormonal therapy and radiotherapy.
Introduction

The need for predictive factors
Clinical cancer research requires that we study populations of patients with similar diseases, in order to define the best therapy for that particular population. After several decades of this type of research, we have established, for example, that almost all populations of patients with breast cancer benefit from chemotherapy. In the adjuvant setting, it has been shown that combination chemotherapy reduces the risk of death at 10 years of follow-up by 27% in women < 50 years old, and by 11% in women 50-69 years old, regardless of nodal status [1] . In the metastatic setting, chemotherapy prolongs time to disease progression, quality of life, and survival [2] .
Such grouping of patients who share a number of clinical characteristics has yielded, and will continue to yield, valuable information on the optimal clinical management of the majority of our patients. There will always be individual patients, however, whose particular features are lost among those of the population, whose disease may behave differently to that of the majority of patients, and who may be best-served by the therapy that appears less effective when applied to the population as a whole. We need markers that can accurately identify these patients, thus splitting our apparently uniform populations into clear sub-populations, and sub-subpopulations, so that the therapies we offer patients may eventually become a reflection of their individual therapeutic needs, rather than the result of the assumption that all patients behave as the population median.
The oncology literature now contains many studies of proteins that are overexpressed or mutated in a percentage of breast tumours, and that may predict sensitivity or resistance to particular therapies. This paper will review the evidence for the predictive value of the three tumour proteins for which significant bodies of clinical data exist in breast cancer; HER-2, p53 and BCL-2.
The definition of a predictive factor
Interpretation of the literature is made complex by the arbitrary use of the word 'predictive' in relation to tumour-related proteins. It is important to differentiate between the prognostic and the predictive value of such proteins.
A prognostic factor is any feature of the patient or the tumor that can be used to predict the patient's natural history in terms of survival. The strongest prognostic factors form the basis of our staging systems, and in breast cancer include presence or absence of distant metastases, nodal status and tumour size. A marker has predictive value only if its presence or absence signals resistance or sensitivity to a particular therapy; it may or may not have prognostic value as well. The only established examples of molecular predictive factors in breast cancer are oestrogen (ER) and progesterone (PR) receptor status for response to hormonal therapy. Thus patients whose tumours strongly express ER or PR are very likely to respond to tamoxifen, or other hormonal manipulations, while patients with receptor-negative tumours do not benefit from hormonal therapy [3] . Similarly, HER-2 status is now used to select patients for therapy with trastuzumab (Herceptin®), as the trials which demonstrated efficacy of this therapy were in patients with HER-2 overexpressing tumours [4, 5] . Resistance to therapy in patients with non-overexpressing tumours has not yet been formally demonstrated, however, so the predictive value of HER-2 for response to trastuzumab is currently assumed rather than proven. Clinical predictive factors for systemic therapies include disease free interval, response to prior therapies, the site and number of metastatic lesions and performance status [2] .
The difference between the prognostic and predictive value of a marker is displayed graphically in Figure 1 .
Rationales for the hypotheses of a predictive value of HER-2,p53 and BCL-2 in breast cancer
HER-2
HER-2 (c-e/-6B-2/neu) is a tyrosine kinase receptor located on the cell membrane of both normal and tumour cells. Activation of the receptor induces activation of ras and a phosphorylation cascade in cytoplasmic kinases, that results in the activation of nuclear transcription proteins, and cellular growth [6] . Additionally, activated proteins from this pathway, such as raf, play an important role in the regulation of proteins of the BCL-2 family, which regulate the apoptotic cascade [7, 8] . HER-2 is overexpressed in approximately 25% of breast cancers.
HER-2 and anti-cancer therapies
In pre-clinical models, transfection of HER-2 into MCF-7 (ER-positive, tamoxifen sensitive) cell lines was shown to induce resistance to both cisplatin and to tamoxifen [9] .
At a molecular level, no clear explanation for this observation is yet apparent. No consistent pattern of apoptotic protein phosphorylation has yet been described in association with HER-2 overexpression, although this would be a possible mechanism of chemoresistance or sensitivity. The function of the oestrogen receptor is also regulated by phosphorylation [10] , and it is possible that HER-2 could thus influence the cellular response to hormonal therapy. Further research is required to better understand these interactions. p53 is a nuclear protein that detects genetic damage and triggers genetic repair mechanisms. In the case of irreparable DNA damage,p53 instead triggers apoptosis (programmed cell death), thus preventing replication of damaged DNA. When p53 is mutated, it may lose its ability to perform this function. Mutant p53 has a prolonged half-life when compared to the wild-type protein, and therefore accumulates in the nucleus of cells [11] . Thus immunohistochemical detection of p53 indicates the presence of mutant p53, and is seen in approximately 25% of breast cancers [12] .
p53 and anti-cancer therapies
It is now established that tumour cell death following exposure to chemotherapy or radiotherapy occurs by apoptosis, and is a p53-dependent event [13] . Thus, chemotherapy and radiotherapy induce DNA damage, p53 detects that damage and, unable to repair it, triggers apoptosis. It has therefore been suggested that reduced levels of functional p53 would prevent chemotherapy-or radiotherapy-induced cell death, and that detectable levels of (mutant) p53 should be a marker of resistance to these therapies [14] .
Cell death following exposure to hormonal therapy also occurs by apoptosis [15] , but the molecular mechanism of this is poorly understood. Hormonal therapies, unlike chemotherapy and radiotherapy, do not damage DNA, and it is therefore not known whether p53 is integral in hormone-induced cell death.
BCL-2
BCL-2 is a member of a family of cytoplasmic proteins (the BCL-2 family) whose transcription is regulated by p53 [11] , and whose activity is regulated by phosphorylation by tyrosine kinases. Some family members promote apoptosis (e.g. Bax, Bad) while others inhibit it (e.g., BCL-2, BCL-X]J. These proteins form multimers, which act as pores in cell membranes, controlling the flux of molecules between cellular compartments [16] . BCL-2 inhibits apoptosis by inhibiting the release of cytochrome-c (Apaf 2) and apoptosis inducing factor (AIF) from the mitochondria to the cytoplasm [17, 18] , and by preventing the activation of caspase 3 (one of the central proteins of the apoptotic pathway) through inhibition of its activator protein, Apaf 1 [19, 20] .
BCL-2 and anti-cancer therapies
BCL-2 overexpression is classically associated with follicular lymphomas. These low-grade tumours grow very slowly over many years, and patients usually experience few symptoms until the tumour transforms to a higher grade, at which stage the disease grows rapidly and is usually fatal [21] . This clinical behaviour is a reflection of BCL-2 overexpression: tumours have low proliferative potential as BCL-2 does not affect cell cycle regulation, but inhibition of apoptosis by BCL-2 results in prolonged cell survival. Transformation to high-grade lymphoma occurs when random mutations of cell cycle regulators accumulate as the result of the extended life span of the tumour cells [22] .
The chemoresistance exhibited by low-grade lymphomas also appears to be mediated by BCL-2. Overexpression of this protein inhibits the activation of apoptotic proteins that would normally be induced by the DNA damage caused by chemotherapy or radiotherapy [22] .
Far less is known about BCL-2 in breast cancer than in lymphoma, but in both tumours it identifies relatively indolent tumour cells. In breast cancer, BCL-2 overexpression occurs in 25%-50% of tumours and frequently correlates with low proliferative indices and high ER content. As BCL-2 is down-regulated by both wild-type and mutant p53, coexpression of these two proteins is uncommon [23] .
As the prognostic implications of BCL-2 overexpression appear to be similar in lymphoma and breast cancer, it is not unreasonable to hypothesise that the resistance to chemotherapy and radiotherapy associated with this protein in lymphoma may also apply to breast cancer. It is not yet established whether hormonally induced apoptosis involves proteins upstream or downstream of BCL-2. If hormonal therapy acts upstream of BCL-2, it is reasonable to suggest that BCL-2 may be predictive of resistance to therapy. If hormonal therapy The levels of evidence used in this review are defined in Table 1 and have been modified from the scales used by ASCO [24] and the American NCI [25] for their tumour marker guidelines. Both of these scales have been designed to assess the value of markers for screening, diagnosis, prognosis and prediction of response to therapy. As this paper addresses only those studies that address the predictive value of the markers, we have more specifically defined certain criteria.
HER-2
Hormonal therapy (see Table 2 ) Two level 2 studies have been published addressing HER-2 as a predictive factor for hormonal therapy in breast cancer, both in metastatic disease. Leitzel et al. demonstrated a response rate to megestrol acetate or fadrozole of 41% in patients with normal HER-2 expression, but only 21% in overexpressors (P -0.004) [26] . Elledge et al. [27] were unable to demonstrate any predictive value of HER-2 for tamoxifen (response rates HER-2-57% vs. HER-2+ 54%, P = 0.67). Of the level 3 studies, two of the three supported Leitzel's conclusion that HER-2 is predictive of resistance to hormonal therapy. In a study of droloxifene for metastatic disease, Yamauchi et al. demonstrated a response rate of 56% in patients with normal HER-2 expression, but only 9% in HER-2 overexpressors (P = 0.0001) [28] . In the adjuvant setting, Carlomagno et al. demonstrated a benefit in terms of disease free survival (P = 0.003) for patients with normal HER-2 expression receiving tamoxifen, but no benefit in HER-2 overexpressors (P = 0.3). It is of some concern that these authors demonstrated a significant worsening in overall survival (P = 0.03) in HER-2 overexpressors, but the benefit of tamoxifen to patients with normal HER-2 expression did not reach statistical significance (P -0.09), suggesting that this finding may be due to statistical error [29] . The third study, published by both Nicholson et al. [30] and Archer et al. [31] , demonstrated that HER-2 predicted resistance to zoladex ± tamoxifen for locally advanced or metastatic disease, but cautioned that this predictive value was not independent of EGFR status [30] , and that the results did not reach statistical significance when the study was repeated using a second antibody in a significant subset of the same set of patients [31] .
Although all of these studies controlled for hormonal receptor status, as HER-2 overexpression frequently correlates with oestrogen and progesterone receptor negativity [27, 32] , only the negative study [27] specifically excluded patients whose ER status was unequivocally negative (< 3 fmol/mg) or unknown.
Anthracycline-based chemotherapy (see Table 3 ) Three level 2 studies have been published to date. In 1994, Muss et al. [33] published a study of 397 patients (CALGB 8541) who were treated in a clinical trial of 1572 patients which compared three dose schedules of cyclophosphamide/doxorubicin/5-fluorouracil (CAF) chemotherapy: 600/60/600 mg/m 2 x 4 (total dose of doxorubicin 240 mg/m 2 , 'high' dose), 400/40/400 x 6 (total dose of doxorubicin 240 mg/m 2 , 'moderate' dose), or 300/30/300 mg/m 2 x 4 (total dose of doxorubicin 120 mg/m 2 , 'low' dose) as adjuvant therapy for patients with node-positive breast cancer. At a median follow-up of three years, they found that in those patients whose tumours were classified as HER-2 high (29% of patients), there was a significant difference in DFS and OS between the three dose levels, while in those classified as HER-2 low, no dose-response effect was seen. The authors concluded that HER-2 overexpression might be a marker of potential benefit from 'high' doses of adjuvant chemotherapy. It was noteworthy that the absolute DFS and OS of HER-2 high patients treated with the optimal CAF dose was longer than that of the HER-2 low patients receiving the same therapy, despite the negative prognostic impact of HER-2 overexpression, suggesting that HER-2 overexpression might be a marker of absolute sensitivity to anthracyclines, but this difference did not reach statistical significance. Makris et al, 1997 (57] Staletal., 1995 [48] Tetuetal., 1994 [58] Giaietal., 1994 [ The update of this study by Thor et al. [34] in 1998 added a further 7 years of follow-up to the original 397 patients, and included 595 extra patients, for a total of 992 patients with a median follow-up 9 years. The percentage of patients with HER-2 overexpression remained steady at 27% with the addition of the new patients. Although the analysis of the new set of patients, in isolation from the patients of the original analysis, could not confirm the findings of the original study without adjustments for prognostic factors (the 'new' HER-2 high patients who received the 'low'-dose CAF had a significantly better survival than those of the original cohort (five-year DFS 63% vs. 31%) due to differences in nodal status, tumour size, menopausal status, ER status and tamoxifen use between the two groups), the updated analysis of all available patients confirmed the dose-response effect in the HER-2 high patients. The updated comparison of HER-2 high and HER-2 low patients who received the 'high'-dose CAF showed that the eight-year DFS and OS of the HER-2 high group (69% and 78%, respectively) remain higher than those of the HER-2 low group (55% and 65%), but these differences still do not reach statistical significance. As a final note, in the small group of HER-2 high patients who also overexpressed p53 (n = 101) a statistically significant dose-response effect was demonstrated. Those who received the 'high' dose of CAF (n -34) had a 10-year OS of over 90%, while those who received the 'low' dose (n = 33) had an OS of 39%. This observation requires further investigation.
Paik et al. [32] (NSABP B-ll) confirmed the CALGB's finding of a correlation between HER-2 overexpression and response to adjuvant anthracycline by demonstrating a clear benefit from the addition of doxorubicin to a combination of melphalan and 5-fluorouracil in HER-2 overexpressors (10-year DFS 39% vs. 24%, P = 0.001), while no benefit was evident in the patients with normal HER-2 expression (10-year DFS 36% vs. 40%, P = 0.74). The findings of Clahsen et al. [35] (EORTC, perioperative FAC x 1 vs. observation, n -440) are also consistent with the findings of the CALGB study in patients with normal HER-2 expression. A benefit in disease free survival of borderline significance (P = 0.05) was demonstrated in patients with normal HER-2 expression. Only 60 patients were evaluable in the HER-2 overexpressor group, and predictably no benefit was demonstrated.
Two level 3 studies [36] [37] [38] have been performed, none of which demonstrated any predictive value of HER-2 for anthracyclines. (Table 4) In a level 2 study, Gusterson et al. [39] demonstrated that in node-positive patients with normal HER-2 expression, six-year survival was significantly longer in patients who received six courses of adjuvant CMFP than in those who received a single course of the same therapy (52% vs. 36%), while in the HER-2 overexpressed group no benefit was demonstrated (38% vs. 29%). This may indicate that HER-2 overexpression is predictive of resistance to CMF, but it is just as likely to be a reflection of the relatively small number of patients in the HER-2 overexpressed group (n = 140). No predictive value of HER-2 was demonstrated in 760 node negative patients in the same study who were randomised between a single course of perioperative CMFP and observation. The only level 3 study [40] (n -613) demonstrated benefit from adjuvant CMFP in HER-2 non-overexpressed patients (P = 0.0003), but no clear benefit in HER-2 overexpressors. In the HER-2 overexpressed group, however, the patient numbers were again small (n = 35-40 per arm), and the disease free survival of the untreated patients was unusually long, so benefit would be difficult to demonstrate.
Non-anthracycline chemotherapy
A single level 3 study (n -122) by Baselga et al. [41] , demonstrated a response rate of 36% in patients with normal HER-2 expression and 65% in HER-2 overexpressed patients, suggesting that HER-2 overexpression might predict relative sensitivity to taxanes. This finding needs confirmation.
Radiotherapy (see Table 5 ) Only one level 3 study [36] has addressed HER-2 as a potential predictive factor for response to radiotherapy in breast cancer. No predictive value was demonstrated.
p53
Hormonal therapy (see Table 6 ) Two level 2 studies [42, 43] have assessed the utility of p53 as a predictive marker in the hormonal therapy of metastatic breast cancer. Elledge et al. [42] were unable to demonstrate any predictive value of immunohistochemically defined p53 status, while Berns et al. [43] found that p53 positivity, assessed by luminometric immunoassay of cytoplasmic extracts, was predictive of resistance to tamoxifen (response rates 57%, 56%, 48% and 37%, from lowest quartile of p53 expression to highest). The only level 3 study [31] could not demonstrate any predictive value.
Anthracycline-based chemotherapy (see Table 7 ) Two level 2 studies [33, 35] and two level 3 studies [36, 37] have assessed the value of/755 as a predictive marker for the efficacy of anthracycline-based chemotherapy in breast cancer. Of the level 2 studies, Clahsen et al. [35] found that p53, assessed immunohistochemically in 440 patients, was predictive of resistance to a single perioperative course of FAC. In the p53 negative patients, perioperative chemotherapy resulted in significantly better four-year survival (88% vs. 77%, P < 0.01), while in the p53 positive patients, no advantage was demonstrated. Muss et al. [33] could not demonstrate any predictive value in a study of 394 patients. Neither of the level 3 studies demonstrated any predictive value.
Of the level 4 studies, the study of Aas [44] is noteworthy, as it assessed the clinical impact of specific p53 mutations. Although the study is limited, the authors suggest a correlation between resistance to doxorubicin and mutations in the L2-3 zinc-binding domain of the p53 protein. If chemoresistance is in fact linked to such a specific defect, p53 status assessed immunohistochemically would include a large number of false positive cases, and this may explain why immunohistochemistry has so far failed to convincingly demonstrate any predictive value for this protein.
Non-anthracycline chemotherapy (see Table 8 ) The only level III study of p53 and a CMF-based regimen [45] did not demonstrate any predictive value. Of the level 4 studies, resistance to 5-FU (in combination with radiotherapy) [46] , and sensitivity to CMF [47] have both been suggested.
The only published study of p53 as a predictive marker of response to a taxane (paclitaxel) for breast cancer included only five patients [49] .
Radiotherapy (see Table 9 ) One level 2 study by Silvestrini et al. [50] and one level 3 study [36] have assessed p53 as a predictive marker for response to radiotherapy. Neither concluded predictive value. Of the three level 4 studies, two suggested that/?55 might be predictive of resistance to radiotherapy [46, 47] , while the other suggested that it was predictive of sensitivity [51] .
BCL-2
Hormonal therapy (see Table 10 ) A single, level 2, study by Elledge et al. [42] has assessed BCL-2 as a predictive marker for hormonal therapy. In ER-positive patients, no predictive value was demonstrated.
Chemotherapy (see Table 11 ) A single, level 2, study has been published, van Slooten et al. [23] did not demonstrate any predictive value of BCL-2 for a single cycle of perioperative FAC chemotherapy in a study of 423 patients.
Radiotherapy
Again a single, level 2, study has been published. Silvestrini et al. [50] did not demonstrate any predictive value of BCL-2 for radiotherapy in a study of 573 patients. 
Discussion
Methodological limitations of current predictive factor studies
Study design
To date, the majority of studies that attempt to identify, confirm or refute the predictive value of a marker have been performed as retrospective companion studies to prospective clinical trials. Such trials are designed to answer a clinical question, with clinical primary endpoints. All of the current studies assessing the predictive value of tumour-related proteins are sub-group analyses of these trials, and should be interpreted accordingly.
The endpoints used in predictive marker studies are very important, as they must allow us to differentiate between the predictive and the prognostic value of a proposed marker. This is well illustrated by the example of ER expression, whose predictive value in respect to hormonal therapies has long been suspected. As ER positivity is a prognostic factor for improved survival regardless of therapy, it has taken an overview of nearly 8000 women with ER-negative tumours treated with tamoxifen to confirm the relationship between ERnegativity and hormone resistance with sufficient confidence to recommend that there is no indication for tamoxifen as therapy for ER-negative tumours [3] .
The cleanest clinical endpoint for a study of a predictive factor is response rate in measurable disease (this implies that the clinical study is performed in metastatic or neoadjuvant settings).
The other endpoint that is used is survival, as it is a very clean endpoint for clinical trials, and it is easily verified. Survival is a relatively weak endpoint for studies of predictive factors, however, as it may be influenced both by therapies subsequent to that being studied in the clinical trial, and, probably more importantly, by the prognostic value of the marker being studied. Studies that use survival endpoints but lack a control arm address only the prognostic value of the marker in patients receiving a particular therapy, and do not provide any useful information regarding its predictive value.
Statistical issues
The interpretation of the current predictive studies is limited by a number of statistical issues:
Firstly, the trials that use response as a clinical endpoint are usually performed in metastatic disease. These trials are relatively small compared to adjuvant trials, and so usually lack statistical power in the subgroup analyses that are required to assess the predictive value of a marker.
Secondly, tissue samples are usually available from only a percentage of the patients in the clinical trial, as retrieval of tissue samples from primary tumours several years after diagnosis is almost always logistically challenging, and biopsy of metastases is usually impractical.
Thirdly, a low prevalence of marker-positivity will further reduce the power of the study. The lower the prevalence, the less stable the comparison between the marker-positive and marker-negative populations will be, particularly if the total number of evaluable patients is small. The effect of this is most evident in studies that compare results in two arms of a randomised trial. Such studies usually seek to demonstrate a statistically significant difference in survival between treatment arms in marker-positive patients, and a non-significant difference in the marker-negative patients, with the conclusion that marker positivity is predictive of resistance to the therapy in question. However, a significant difference will always be more difficult to demonstrate in the smaller, marker-positive group than in the larger, marker-negative group, so such results must always be interpreted in light of the absolute number of evaluable patients in the marker-positive group.
Marker assays
There are a number of limitations in the assays of markers that are used in these studies, which should not be ignored. The majority of studies have assessed the value of the markers assessed by immunohistochemistry using monoclonal antibodies, as this method is widely available, is able to be performed on stored tumour samples and is comparatively cheap. However, this method assesses only the presence or absence of a protein, without necessarily providing information regarding the form (e.g., wild-type vs. mutant, phosphorylated vs. unphosphorylated) or function of that protein. In addi-tion, as no international standards yet exist, the definitions of marker positivity and negativity are defined individually by each study, and interobserver variation in reporting tumour marker status may limit the reproducibility of study results.
Gene studies are more expensive, and less widely available, but attempt to bypass some of the interobserver discrepancies, and to provide more details of the mutation being studied. Unfortunately, we are still trying to define which mutations of each marker have functional sequelae, so that at present most studies still only compare patients with any mutation to those with wild-type protein.
HER-2
At this time, the most promising candidate as a predictive factor for breast cancer is HER-2. The current data suggest that it might be predictive of resistance to hormonal therapy and it is probably predictive of relative sensitivity to anthracycline-based chemotherapy. To date, trastuzumab has only been studied in patients with HER-2 overexpressing metastatic breast cancer [4, 5] , and HER-2 status is therefore used for selection of patients for this therapy, although resistance in patients with tumours with normal HER-2 expression has not yet been formally demonstrated.
All five studies that have addressed HER-2 as a predictive factor for hormonal therapy (level 2 or 3) have demonstrated lower response rates, or reduced survival in hormonally treated patients, in the patients whose tumours overexpress HER-2, reaching statistical significance in three of the five studies. Although it is possible that these findings are due to either the failure to exclude ER-negative tumours (which would be likely to be over-represented in the HER-2-positive group) in most of the studies, or to an interaction with EGFR, the overall picture supports the preclinical finding that MCF-7 cells are rendered tamoxifen resistant following HER-2 transfection.
A limitation of these findings is that it is relatively uncommon for tumours to co-express hormone receptors and HER-2. Our own review of two recent EORTC chemotherapy trials (EORTC 10921 and EORTC 10923) restricted the ER+/HER-2+ phenotype to only 7% of those patients with known HER-2 status (n = 249), or 16% of the ER+ sub-population (n = 115). Nevertheless, the importance of these findings to this subgroup may be substantial.
The evidence for HER-2 as a predictor of sensitivity to anthracycline-based chemotherapy is more consistent.
The CALGB's finding [33] that node-positive patients who overexpress HER-2 received greatest benefit from 'high'-dose CAF added nothing to the results of the intact clinical study, which had established the 600/60/ 600 x 4 schedule as the CAF standard, regardless of HER-2 status. The failure to demonstrate a doseresponse in HER-2 low patients was more difficult to interpret. Firstly, it was possible that HER-2 low patients were exquisitely sensitive to anthracyclines, so that dose escalation exceeded the maximal effect of the drug. This scenario seemed unlikely, however, as the intact clinical trial clearly demonstrated a dose-response effect in the undivided population, the majority of whom would have been HER-2 low. Secondly, it was possible that low HER-2 expression conferred resistance to CAF chemotherapy at any dose. There is a certain logic to this hypothesis if, as has been proposed, HER-2 is only a surrogate marker for topoisomerase Ha (the target enzyme of anthracyclines) [52] . Thus, lack of expression of HER-2 would imply a relative absence of topoisomerase Ila, which would be expected to correlate with clinical resistance. However this would be in conflict with the results of other clinical trials which had conclusively demonstrated the efficacy of anthracyclines in patients unselected for HER-2 status, the majority of whom would again have been HER-2-negative.
Thus this failure to demonstrate a dose-response effect in HER-2-negative patients did not lie comfortably with the results of either the intact clinical trial, which favoured an overall dose-response effect, or the other clinical trials, which had established the efficacy of anthracyclines in breast cancer patients unselected for HER-2 status, of whom 70%-80% would have been HER-2-negative. It was very possible, therefore, that the result was a statistical error, due to the relatively high survival of these patients (at the median follow-up of only three years in this report, DFS was approximately 75% and OS was approximately 90%) and the three-way randomisation of only 283 patients. Ultimately, no definitive conclusions regarding HER-2 low patients were drawn from this study.
The comparable survival data in optimally treated HER-2 low and HER-2 high patients was an interesting observation, as it suggested that the 'high'-dose CAF was able to overcome the negative prognostic implications of HER-2 overexpression, while the lower doses were not. In short, the study demonstrated that suboptimal doses of CAF were sub-optimal therapy for node-positive HER-2 overexpressors.
The confirmatory results in the HER-2 high group of the CALGB update analysis [34] were noteworthy. Possibly more importantly, however, the addition of additional patients and follow-up revealed that the HER-2 low patients were also deriving benefit from 'high'-dose CAF. In the HER-2 low group, the interaction between CAF dose and OS was statistically significant (P -0.048), while the interaction between CAF dose and DFS was of borderline significance (P = 0.058). This was a reassuring observation, as the results in the companion study had now become consistent with the results of the clinical study. In the light of the updated results, we can therefore still conclude that sub-optimal doses of CAFare sub-optimal therapy for node-positive HER-2 overexpressors, but we can now state that suboptimal doses of CAF are sub-optimal therapy for node-positive HER-2-negative patients as well.
The update of the comparison of optimally treated HER-2 low and HER-2 high patients also confirmed the suggestion that HER-2 overexpression conferred an absolute sensitivity to optimally dosed CAF, but again this did not reach statistical significance, and therefore this remains a hypothesis. The NSABP's finding of a correlation between HER-2 overexpression and response to adjuvant anthracycline [32] is entirely consistent with the CALGB data. The lack of apparent benefit from anthracycline in the HER-2-negative group in this study is less pertinent than in the original CALGB report, as a greater percentage of the patients (38%) in the NSABP study was HER-2-positive. Thus a significant benefit in this large subpopulation could conceivably influence the outcome of the clinical trial.
The results of the EORTC study [35] are consistent with, but do not confirm, the results of the other two level 2 studies. The results of the two level 3 studies are also consistent, but do not reach statistical significance, while the third studies mitoxantrone.
While none of these studies provides conclusive evidence that HER-2 positivity is a marker of absolute sensitivity to anthracyclines (HER-2 positivity and negative patients who receive optimal anthracycline doses have similar survival), and none conclusively demonstrates that HER-2 status is able to predict response to anthracycline based therapy (benefit is seen in both HER-2-positive and HER-2-negative patients), all three level 2 studies are consistent with the conclusions that HER-2 overexpressing tumours are anthracycline responsive (i.e., HER-2 is clearly not a marker of anthracycline resistance), and that patients whose tumours overexpress HER-2 appear to receive the greatest relative benefit from this therapy.
A lone study has suggested that HER-2 is a marker of resistance to CMF [39] . The potential pitfall in the interpretion of this study is that the percentage of HER-2-positive patients was relatively small (19%, n -118). As described earlier, however, the chance of detecting a significant effect of therapy in a cohort of this size is very small, and as the conclusion of resistance is based upon the inability to demonstrate an effect in this group, the result must be interpreted with extreme caution.
The interaction between radiotherapy and HER-2 remains inadequately assessed.
P 53
The current data on the predictive value ofp53 have not provided convincing data to support the hypothesis that p53 is a predictive factor for any breast cancer therapy. There are a number of reasons why this may be so.
The most obvious possibility is that imunohistochemistry of p53 is an inadequate method of assessing the function of this protein. This theorem gains some weight from the fact that, of the thirteen (level 2-4) published studies that assessed p53 by IHC, only two demonstrated any predictive value. In contrast, both of the studies that assessed p53 by DNA sequencing, and the only study that used immunometric immunoassay of cytosol extracts, concluded predictive value. Thus it seems reasonable to suppose that IHC, which detects any accumulated p53, is not sufficiently specific to differentiate between those mutations with functional sequelae, and those without. This needs to be further investigated.
Secondly, other proteins in the apoptotic cascade affectp53's function. Thus it is possible, thatp53 dysfunction in isolation would not lead to therapy resistance but, in combination with dysregulation of certain other proteins, therapy resistance may occur. Although an interesting concept, this is very difficult to study in the clinical setting due to the large number of possible secondary proteins.
Finally, p53 may just be too non-specific to be a useful predictive marker.
BCL-2
BCL-2 remains inadequately studied as a predictive factor in breast cancer.
Conclusions and future directions
With the exception of trastuzumab, which is now registered for use in patients whose tumours overexpress HER-2 as detected by the Herceptest®, we do not yet have sufficient evidence to recommend the use of HER-2, p53 or BCL-2 in the selection of therapies for breast cancer. Further studies need to be performed. We will eventually need level 1 studies to confirm the predictive value of proposed molecular markers, as metaanalyses will be almost certainly be invalidated by editorial and reporting bias. Unlike clinical trials, which are usually eventually reported even if negative, companion studies are easily left unpublished if no significant result is demonstrated.
There is now sufficient level 2 and 3 evidence that HER-2 may be predictive of resistance to hormonal therapy to justify a level 1 trial. Such a trial will be difficult to design however, as HER-2+/ER+ patients are uncommon, and hormonal therapy versus no treatment/placebo would not be ethical in the metastatic setting. As chemotherapy is rarely combined with hormonal therapy in metastatic disease, and an active agent would need to be given on each arm, the only possibility in metastatic disease would be a randomisation of HER-2+/ER+ patients between an anti-HER-2 therapy, such as herceptin, given as a single agent versus the same agent in combination with hormonal therapy. Ideally, both sequential therapy and concurrent administration of the two agents would be investigated. Such a design demands the rather large assumption that no interaction exists between the two therapies. The trial would need to be powered as for equivalence, and it would be imperative to document PR and EGFR status. In the adjuvant setting, a design of chemotherapy alone versus chemotherapy followed by tamoxifen would be ideal in theory, but in practice would be difficult to support, as it is unlikely that either clinicians or patients would accept withholding an established therapy such as tamoxifen, which is so well tolerated without additional evidence from the metastatic setting.
Regarding HER-2 and chemotherapy, the main clinical issue that now arises is whether HER-2 status can define those patients who should preferentially receive anthracycline-based (e.g., AC) or CMF adjuvant therapy. The current data suggest that anthracyclines are effective therapy for breast cancer, regardless of HER-2 status, and that CMF is effective therapy for HER-2 negative disease, but remains inadequately studied in HER-2 overexpressing disease. As the evidence for resistance to CMF in HER-2 positive patients is unconvincing at this time, CMF should continue to be presumed effective in this sub-group, on the basis of Bonnadonna's convincing long-term data in patients who were unselected for HER-2 status [53] .
Although this paper has not attempted to review studies that have been reported only as abstracts, three recent presentations are of particular interest. Analysis of Bonadonna's original CMF trial has demonstrated benefit from CMF in HER-2-positive patients (level 3 evidence) [54] . In addition, two large clinical trials comparing anthracycline-based therapy to CMF in the adjuvant setting have been analysed. Neither the level 2 evidence study NSABP B-15 (AC vs. CMF vs. AC followed by CMF) [55] nor the level 3 Belgian study (EC vs. CMF) [56] were able to demonstrate a statistically significant difference in outcome in the HER-2 positive population. Two other large trials of similar design (INT 0102 (CAF vs. CMF) and the Canadian study (CEF vs. CMF) remain to be analysed.
As the taxanes move into the adjuvant setting, evaluation of HER-2 expression as it relates to sensitivity to taxanes is now a research priority.
For p53, the current priority must be to establish the optimal assay method, preferably in level 2 studies.
Further level 2 and 3 studies of BCL-2 are required before any conclusions can be drawn about the role of BCL-2 in the therapy of breast cancer. The role of BCL-2 in the efficacy of hormonal therapy will be particularly important to address, as BCL-2 and hormone receptors are frequently coexpressed in breast cancer.
The role of BCL-2 expression in the response to taxane therapy will also be very interesting as paclitaxel has been shown to inactivate BCL-2 by phosphorylation [7] .
It is unfortunate that studies with levels of evidence of 4 and 5 continue to be performed and published as studies of predictive value. These studies add little to our understanding of the molecular mechanisms of resistance to therapy, nor to our clinical ability to predict response to a particular therapy. Although useful to generate hypotheses regarding newly recognised markers, such studies are well surpassed for the three markers reviewed in this paper, and additional low level studies will only serve to further confuse an already difficult area of the literature.
